The study profiled plasma and excised vegetation samples from 238 infective-endocarditis patients and 100 controls, then used an ensemble machine-learning pipeline to select a 10-protein plasma diagnostic panel. The paper reports AUCs of 0.97 in the held-out discovery test set and 0.98 and 0.94 in two external plasma cohorts. Integrating proteomic and clinical features also produced a prognostic model for severe heart-failure status (abstract AUC 0.87). LRG1 and NDUFB4 were associated with infection severity in the cohort analyses.
Technology: Ensemble machine-learning diagnostic and prognostic models; the diagnostic workflow compared six algorithms and used recursive feature elimination with cross-validation to select a 10-protein panel
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The paper reports AUCs of 0.97 in the held-out discovery test set and 0.98 and 0.94 in two external plasma cohorts.
- Still unknown: The study is an observational proteomic cohort analysis; it does not demonstrate that use of the panel improves patient outcomes or can replace current diagnostic criteria. The development comparison included 238 IE patients and 100 controls, so case-control separation may not reflect performance in an unselected real-world diagnostic population. External evaluation used two additional plasma cohorts (combined n=328); the prognostic endpoint and biomarkers are associations, not causal mechanisms. The paper's proposed NET-related therapeutic implications are hypothesis-generating and are not counted as demonstrated treatment benefit.
- AI role: Machine-learning feature-importance analysis and recursive feature elimination selected a 10-protein plasma combination for distinguishing infective endocarditis from non-endocarditis samples. The models were evaluated in a held-out discovery cohort and two external plasma cohorts. A separate model combined proteomic and clinical features to classify severe heart-failure status.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40447567/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 10 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A multicenter observational serum multi-omics study used LASSO and Boruta to select candidate biomarkers for 28-day outcome in acute respiratory distress syndrome. Eight proteins (VCAM1, LDHB, MSN, FLG2, TAGLN2, LMNA, MBL2 and LBP) showed consistency in an independent cohort of 183 patients and were confirmed by targeted parallel-reaction-monitoring mass spectrometry. The protein model AUC was 0.802 in validation versus 0.738 for the clinical model. The discovery analysis also reported sphingosine-1-phosphate association with ARDS prognosis and an enriched sphingolipid pathway.
Technology: LASSO and Boruta feature selection; machine-learning prognostic model; targeted PRM validation
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Eight proteins (VCAM1, LDHB, MSN, FLG2, TAGLN2, LMNA, MBL2 and LBP) showed consistency in an independent cohort of 183 patients and were confirmed by targeted parallel-reaction-monitoring mass spectrometry.
- Still unknown: Observational prognostic associations do not show proteins cause outcomes or that biomarker-guided care improves survival. Discovery n=130 ARDS patients; validation n=183. PRM confirmation is not independent replication by another group; deployment and prospective benefit were not established.
- AI role: LASSO, fold-change screening and Boruta prioritized candidate 28-day ARDS prognostic proteins; candidates were tested by targeted PRM in an external cohort.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/38956604/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 41 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning and quantum-chemistry workflow screened ionic liquids for conductivity and electrochemical-window properties, then guided selection for rigid-rod polyelectrolyte membranes. The 2022 preprint reports ~50 μm membranes and lithium-cell testing, including symmetric-cell cycling up to 800 hours at room temperature and reversible operation at 6 mA cm−2 at 80°C. Its preprint abstract reports 146 mAh g−1 at 5C/80°C; the later 2023 journal abstract lists 3C, so those version-specific figures are not conflated.
Technology: Graph-convolutional neural network and ensemble SVM/random-forest/XGBoost screening with Psi4 quantum-chemistry descriptors
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The 2022 preprint reports a machine-learning/quantum-chemistry workflow that screened 2,356 ion pairs and recommended 40 for testing in rigid-rod polyelectrolyte membranes. It reports symmetric-cell cycling up to 800 hours at room temperature and reversible operation at 6 mA cm−2 at 80°C; its abstract reports 146 mAh g−1 at 5C/80°C.
- Still unknown: The 2023 journal abstract reports the same study but gives 146 mAh g−1 at 3C rather than 5C. The record keeps the version-specific preprint metric separate and does not transfer it to the journal version. A publisher correction changes plot labels, not the core study claim.
- AI role: Machine-learning models and quantum-chemistry calculations screened ionic-liquid properties and guided selection for experimental polymer-electrolyte membranes and cell testing.
Evidence sources: https://assets-eu.researchsquare.com/files/rs-2220925/v1/0341f570-c3ce-430f-8b00-a72d3fa48184.pdf?c=1684221171 · https://www.nature.com/articles/s41467-023-38493-7 · https://www.nature.com/articles/s41467-023-39621-z
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary Research Square v1 full-text PDF, including version date, affiliations, Methods and Results; primary Nature Communications journal article indexed text and metadata; primary publisher correction notice..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.